Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Benproperine→

Benproperine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2156-27-6
Molecular formula
C21H27NO
Molecular weight
309.4 g/mol
Drug class
Non-opioid antitussivecough suppressant
Mechanism of action
Suppresses the cough reflex through central and peripheral actions; the precise molecular target is not fully established. It is not a mu-opioid receptor agonist.
Indications / reported uses
  • Symptomatic treatment of dry, non-productive cough in countries where benproperine products are authorised; not intended to suppress productive cough where expectoration is required

Sources: NLM MeSH — Benproperine · PubMed — Benproperine antitussive pharmacology · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Non-opioid antitussive; cough suppressant

Mechanism of action

Suppresses the cough reflex through central and peripheral actions; the precise molecular target is not fully established. It is not a mu-opioid receptor agonist.

General use cases

  • Symptomatic treatment of dry, non-productive cough in countries where benproperine products are authorised; not intended to suppress productive cough where expectoration is required

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Benproperine Environmental Risk Assessment (ERA) (the Benproperine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.